Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
Abstract miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD/NASH model. First, male C57BL/6J mice...
Guardado en:
Autores principales: | Rebeca Escutia-Gutiérrez, J. Samael Rodríguez-Sanabria, C. Alejandra Monraz-Méndez, Jesús García-Bañuelos, Arturo Santos-García, Ana Sandoval-Rodríguez, Juan Armendáriz-Borunda |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3d0a5ea6aa3f4130aece7fe0791813bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
por: Jorge Gutiérrez-Cuevas, et al.
Publicado: (2021) -
Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
por: Jorge Antonio Silva-Gomez, et al.
Publicado: (2021) -
John Forbes Nash /
por: Flores, Néstor, et al.
Publicado: (2005) -
Dos nuevos microRNAs (miRNAs) identificados en ovario bovino
por: Muñoz-Bañales,LA, et al.
Publicado: (2014) -
Pre-Analytical Modification of Serum miRNAs: Diagnostic Reliability of Serum miRNAs in Hemolytic Diseases
por: Yukichi Takada, et al.
Publicado: (2021)